Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy
Phase 2
Terminated
- Conditions
- Hypertriglyceridemia
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Medical Research Laboratories International
- Target Recruit Count
- 50
- Registration Number
- NCT00080132
- Locations
- ๐บ๐ธ
The Methodist Hospital, Houston, Texas, United States
๐ณ๐ฑAndromed Rotterdam, Rotterdam, Netherlands
๐ณ๐ฑAndromed Zoetermeer, Zoetermeer, Netherlands
Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy
Phase 2
Terminated
- Conditions
- Familial Hypercholesterolemia
- First Posted Date
- 2004-03-18
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Medical Research Laboratories International
- Target Recruit Count
- 60
- Registration Number
- NCT00079846
- Locations
- ๐จ๐ฆ
Lipid Research Center, CHUL du CHUQ, Sainte-Foy, Quebec, Canada
๐จ๐ฆLipid Clinic and Community Genomic Center, Complexe Hospitalier de la Sagamie, Chicoutimi, Quebec, Canada
๐ฎ๐ฑHadassah University Hospital, Jerusalem, Israel
Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy
Phase 2
Terminated
- Conditions
- Familial Hypercholesterolemia
- First Posted Date
- 2004-03-18
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Medical Research Laboratories International
- Target Recruit Count
- 120
- Registration Number
- NCT00079859
- Locations
- ๐ณ๐ฑ
Andromed Oost, Velp, Netherlands
๐ณ๐ฑAndromed Zoetermeer, Zoetermeer, Netherlands
๐ณ๐ฑAndromed Rotterdam, Rotterdam, Netherlands
ยฉ Copyright 2025. All Rights Reserved by MedPath